Cancer, inflammation and the AT1 and AT2 receptors

Journal of Inflammation

Volumn 1, Issue , 2004, Pages

  Smith, Gary Robert ^a   Missailidis, Sotiris ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANTIINFLAMMATORY AGENT; ASBESTOS; CANCER VACCINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH HORMONE; INTERLEUKIN 1BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG POTENTIATION; ESOPHAGUS CANCER; GENE OVEREXPRESSION; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HUMAN; HYPERTENSION; HYPOXIA; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LARYNX CANCER; LITERATURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG CARCINOMA; MESOTHELIOMA; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCHISTOSOMA HEMATOBIUM; STOMACH ADENOCARCINOMA; UTERINE CERVIX CANCER; WART VIRUS;

EID: 15444365932     PISSN: 14769255     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-9255-1-3     Document Type: Review

References (87)

1. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545.
2. Munger K: The role of human papillomaviruses in human cancers. Frontiers in Bioscience 2002, 7:D641-D649.
3. Castle PE, Hillier S, Rabe L, Hildesheim A, Herrero R, Bratti M, Sherman M, Burk R, Rodriguez A, Alfaro M, Hutchinson M, Morales J, Schiffman M: An Association of Cervical Inflammation with High-Grade Cervical Neoplasia in Women Infected with Oncogenic Human Papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 2001, 10:1021-1027.
4. Syrjanen KJ: HPV infections and oesophageal cancer. Journal of Clinical Pathology 2002, 55:721-728.
5. Aaltonen LM, Rihkanen H, Vaheri A: Human papillomavirus in larynx. Laryngoscope 2002, 112(4):700-707.
6. Naumann M, Crabtree J: Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis. Trends in Microbiology 2002, 12:29-36.
7. Hilleman M: Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003, 21:4626-4649.
8. Rosin MP, Anwar WA, Ward AJ: Inflammation, chromosomal instability and cancer: the schistosomiasis model. Cancer Res 1994, 54(7 Suppl):1929S-1933S.
9. Manninga C, Vallyathanb V, Mossman B: Diseases caused by asbestos: mechanisms of injury and disease development. International Immunopharmacology 2002, 2:191-200.
10. Farrow B, Evers BM: Inflammation and the development of pancreatic cancer. Surgical Oncology 2002, 10:153-169.
11. Schwartsburd PM: Chronic inflammation as inductor of procancer microenvironment: Pathogenesis of dysregulated feedback control. Cancer and Metastasis reviews 2003, 22:95-102.
12. Slaviero KA, Clarke SJ, Rivory LP: Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003, 4:224-32.
13. Thomas WG, Mendelsohn FAO: Molecules in Focus Angiotensin receptors: form and distribution. IJBCB 2003, 35:774-779.
14. Martin MM, Victor X, Zhao X, McDougall JK, Elton TS: Identification and characterization of functional angiotensin II type 1 receptors on immortalized human fetal aortic vascular smooth muscle cells. Molecular and Cellular Endocrinology 2001, 183:81-91.
15. Moore SA, Patel AS, Huang N, Lavin BC, Grammatopoulos TN, Andres RD, Wayhenmeyer JA: Effects of mutations in the highly concerved DRY motif on binding affinity, expression, and G-protein recruitment of the human angiotensin II type-2 receptor. Molecular Brain Res. 2002, 109:161-167.
16. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J: Inflammation and angiotensin II. IJBCB 2003, 35:881-900.
17. Dorffel Y, Latsch C, Stuhlmuller B, Schreiber S, Scholze S, Burmester GR, Scholze J: Preactivated Peripheral Monocytes in Patients with Essential Hypertension. Hypertension 1999, 34:113-117.
18. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M: Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. Journal of the American College of Cardiology 2000, 35:715-721.
19. Chen HC, Bouchie J, Perez A, Clermont A, Izumo S, Hampe J, Feener E: Role of the Angiotensin AT1 Receptor in Rat Aortic and Cardiac PAI-1 Gene Expression. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:2297.
20. Mishima K, Kato J, Kuwasako K, Imamura T, Kitamura K, Eto T: Angiotensin II modulates gene expression of adrenomedullin receptor components in rat cardiomyocytes. Life Sciences 2003, 73:1629-35.
21. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Paul BS, Lai PBS: Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regulatory Peptides 2003, 116:61-69.
22. Rosenkranz S: TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004, 63:423-432.
23. Teicher B: Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer and Metastasis reviews 2001, 20:133-143.
24. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET: Transforming Growth Factor β Inhibits the Antigen-Presenting Functions and Antitumor Activity of Dendritic Cell Vaccines. Cancer Research 2003, 63:1860-1864.
25. Maeda H, Fang J, Inutsuka T, Kitamoto Y: Vascular permeability enhancement in solid tumors: various factors, mechanisms involved and its implications. International Immunopharmacology 2003, 3:319-328.
26. Tahmasebi M, Puddefoot JR, Inwang ER, Goode AW, Carpenter R, Vinson GP: Transcription of the prorenin gene in Normal and Diseased Breast. Eur J Cancer 1998, 34:1777-1782.
27. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K: Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by Angiotensin type 1 receptor antagonist. FEBS Letters 2001, 495:197-200.
28. Goldfarb A, Diz I, Tubbs R, Ferrario M, Novick C: Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 1994, 151(1):208-13.
29. Takeda H, Kondo S: Differences between Squamous Cell Carcinoma and Keratoacanthoma in Angiotensin Type-1 Receptor Expression. American Journal of Pathology 2001, 158:1633-1637.
30. Marsigliante S, Resta L, Muscella A, Vinson GP, Marzullo A, Storelli C: AT1 antagonist II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Letters 1996, 110:19-27.
31. Batra V, Gropalakrish V, McNeill J, Hickie R: Angiotensin II elevates cytosolic free calcium in human lung adenocarcinoma cells via activation of AT1 receptors. J Urol 1994, 151:208-213.
32. Dana K, Blanka Z, Eva S, Vlasta S: Int J Mol Med 1998:593-595.
33. Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell 2000, 100:57-70.
34. Kawamata H, Furihata T, Omotehara F, Sakai T, Horiuchi H, Shinagawa Y, Imura J, Ohkura Y, Tachibana M, Kubota K, Terano A, Fujimori T: Identification of genes differentially expressed in a newly isolated human metastasizing esophageal cancer cell line, T.Tn-AT1, by cDNA microarray. Cancer Sci 2003, 94:699-706.
35. De Paepe, Verstraeten VLRM, De Potter CR, Vakaet LAML, Bullock GR: Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001, 116:247-254.
36. Mehta JL, Li D: Identification, Regulation and Function of a Novel Lectin-Like Oxidized Low-Density Lipoprotein Receptor. J Am Coll Cardiol 2002, 39:1429-1435.
37. Dechend R, Fiebler A, Lindschau C, Bischoff H, Muller D, Park JK, Dietz R, Haller H, Luft FC: Modulating Angiotensin II-Induced Inflammation by HMG Co-A Reductase Inhibition. Am J Hypertens 2001, 14:55S-61S.
38. Nagase M, Ando K, Nagase T, Kaname S, Sawamura T, Fuj T: Redox-Sensitive Regulation of LOX-1 Gene Expression in Vascular Endothelium. Biochemical and Biophysical Research Communications 2001, 281:720-725.
39. Chan WP, Fung ML, Nobiling R, Leung PS: Activation of local renin-angiotensin system by chronic hypoxia in rat pancreas. Molecular and Cellular Endocrinology 2000, 160:107-114.
40. Leung PS, Fung ML, Tam MS: Renin-angiotensin system in the carotid body. Int J Biochem Cell Biol 2003, 35:847-854.
41. Chassagne C, Eddahibi S, Adamy C, Rideau D, Marcotte F, Dubois-Rande JL, Adnot S, Samuel JL, Teiger E: Modulation of Angiotensin II Receptor Expression during Development and Regression of Hypoxic Pulmonary Hypertension. Am J Respir Cell Mol Biol 2000, 22:323-332.
42. Grammatopoulos T, Morris K, Ferguson P, Weyhenmeyer J: Angiotensin protects cortical neurons from hypoxia-induced apoptosis via the angiotensin type 2 receptor. Molecular Brain Research 2002, 99:144-124.
43. Page EL, Robitaille GA, Pouyssegur , Richard DE: Induction of Hypoxia-Inducible Factor-1́ by Transcriptional and Translation Mechanisms. JBC 2002, 277:48403-48409.
44. Brown NS, Bicknell R: Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327.
45. Maluccio M, Sharma V, Lagman M, Konijn G, Suthanthiran M: Angiotensin II Receptor Blockade: A novel Strategy to Prevent Immunosuppressant-Associated cancer Progression. Transplantation Proceedings 2001, 33:1820-1821.
46. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JWK: Do inhibitors of angiotensin-1-converting enzyme protect against risk of cancer? Lancet 1998, 352:179-184.
47. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T, Hayakawa M: Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogenesis. Cancer research 2002, 62:4176-4179.
48. Egami K, Murohara T, Shimada T, Sasaki KI, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T: Role of host angiotensin II type I receptor in tumor angiogenesis and growth. J Clin Invest 2003, 112:67-75.
49. Yu Q, Stamenkovic I: Cell surface-localised matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes & Development 2000, 14:163-176.
50. Jin D, Takai S, Shiota N, Miyazaki M: Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. European Journal of Pharmacology 1998, 361:199-205.
51. Yashiro M, Chung Y, Sowa M: Tranilast [N-(3,4 dimethoxycinnamoyl) anthranilic acid] down regulates the growth of scirrhous gastric cancer. Anticancer Res 1997, 17:895-900.
52. Noguchi N, Kawashiri S, Tanaka A, Kato K, Nakaya H: Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncology 2003, 39:240-247.
53. Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M: [N-(3,4-dimethoxycinnamoyl) anthranilic acid] (Tranilast) inhibits transforming growth factor-beta release and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 2001, 93:53-61.
54. Hiroi M, Onda M, Uchida E, Aimoto T: Anti-tumor Effect of [N-(3,4-dimethoxycinnamoyl) anthranilic acid] (tranilast) on Experimental Pancreatic Cancer. J Nippon Med Sch 2002, 69:224-234.
55. Shime H, Kariya M, Orii A, Momma C, Kanamori T, Fukuhara K, Musakari T, Tsuruta Y, Takakura K, Nikaido T, Fujii S: Tranilast inhibits the proliferation of uterine leiomyoma cells vitro through G1 arrest associated with the induction of p21 (waf1) and p53. J Clin Endocrinol Metab 2002, 87:5610-5617.
56. Abali H, Gullu IH, Engin H, Haznedaroglu IC, Erman M, Tekuzman G: Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Medical Hypotheses 2002, 59:344-348.
57. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y: Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Molecular Cancer Therapeutics 2003, 2(11):1139-1147.
58. Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW: Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. Journal of Chromatography B 1999, 732(1):203-212.
59. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, Imazu H, Fukui H: Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 2002, 20:1227-1231.
60. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clinical Cancer Research 2001, 7:1073-1078.
61. Szlosarek PW, Balkwill FR: Tumour necrosis factor α: a potential target for the therapy of solid tumours. The Lancet oncol 2003, 4:565-573.
62. Apte RN, Voronov E: Interleukin-1, a major pleiotropic cytokine in tumor-host interactions. Seminars in Cancer Biology 2002, 12:277-290.
63. Kobie JJ, Akporiaye ET: Immunosuppressive role of transforming growth factor beta in breast cancer. Clinical and Applied Immunology Reviews 2003, 3:277-287.
64. Adam JK, Odhav B, Bhoola KD: Immune responses in cancer. Pharmacology & Therapeutics 2003, 99:113-132.
65. Eto H, Biro S, Miyata M, Kaieda H, Obata H, Kihara K, Tei C: Angiotensin II type 1 receptor participates in extracellular matrix production in the late stage of remodelling after vascular injury. Cardiovascular research 2003, 59:200-211.
66. Kwang KK, Jeong YA, Sueng HH, Dae SK, Dong KJ, Hyung SK, Mi-Seung S, Ta HA, In SC, Eak KS: Pleiotropic Effects of Angiotensin II receptor blockade in Hypertensive Patients. J Am Coll of Cardiol 2003, 42:905-910.
67. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M: Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. European Journal of Pharmacology 2001, 433:163-168.
68. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL: Endothelial activation by angiotensin II through NfkappaB and P38 pathways: Involvement of NfkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003, 195:402-410.
69. Takemori K, Ito H, Suzuki T: Effects of the AT1 Receptor Antagonist on Adhesion Molecule Expression in Leukocytes and Brain Microvessels of Stoke-Prone Spontaneously Hypertensive Rats. Am J Hypertens 2000, 13:1233-1241.
70. Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G: Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arteriosclerosis, Thrombosis and Vascular Biology 2002, 22:1208.
71. Franscini LMD, Vigier ROV, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG: Effectiveness and Safety of the Angiotensin II Antagonist Irbesartan in Children With Chronic Kidney Diseases. Am J Hypertens 2002, 15:1057-1063.
72. Tsang SW, Ip SP, Leung PS: Prophylactic and therapeutic treatments with AT1 and AT2 receptor antagonists and their effects on changes in the severity of pancreatitis. IJBCB 2004, 36:330-339.
73. Stander H, Stadelmann , Luger T, Traupe H: Granulomatous blephartis successfully treated with Tranilast,. Br J Dermatol 2003, 149:222-224.
74. Perez-Castrillon JL, Silvia J, Justo I, Sanz A, Martin-Luquero M, Igea R, Escudero P, Pueyo C, Diaz C, Hernandez G, Duenas A: Effect of Quinapril, Quinapril-Hydroclorothiazide, and Enalapril on the Bone Mass of Hypertensive Subjects: Relationship with Angiotensin Converting Enzyme Polymorphisms. Am J Hypertens 2003, 16:453-459.
75. Burton T, Liang B, Dibrov A, Amara F: Transforming growth factor-β-induced transcription of the Alzheimer β-amyloid precursor proteingene involves interaction between the CTCFcomplex and Smads. Biochemical and Biophysical Research Communications 2002, 295:713-723.
76. Ge J, Barnes NM: Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders. European Journal of Pharmacology 1996, 297:299-306.
77. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F: Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's disease. Neurobiology of Aging 2001, 22:541-546.
78. Platten M, Eitel K, Wischhusen J, Dichgans J, Weller M: Involvement of protein kinase Cδ and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by [N-(3,4-dimethoxycinnamoyl) anthranilic acid] (Tranilast). Biochemical Pharmacology 2003, 66:1263-1270.
79. Tamura M, Chen YJ, Howard EF, Tanner M, Landon EJ, Myers PR: Lipopolysaccharides and cytokines downregulate the angiotensin II type 2 receptor in rat cardiac fibroblasts. European Journal of Pharmacology 1999, 386:289-295.
80. Li JY, Avallet O, Berthelon MC, Langlois D, Saez JM: Effects of growth factors on cell proliferation and angiotensin II type 2 receptor number and mRNA in PC12W and R3T3 cells. Molecular and Cellular Endocrinology 1998, 139:61-69.
81. Heemskerk VH, Daemen MARC, Buurman WA: Insulin-like growth factor (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine & Growth Factor Reviews 1999, 10:5-14.
82. Khan AS, Sane DC, Wannenburg T, Sonntag WE: Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovascular Research 2002, 54:25-35.
83. Katsanos KH, Tsatsoulis A, Christodoulou D, Challa A, Katsaraki A, Tsianos EV: Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Hormone & IGF Research 2001, 11:364-367.
84. Humbert S, Saudou F: Huntingtin phosphorylation and signaling pathways that regulate toxicity in Huntington's disease. Clinical Neuroscience Research 2003, 3:149-155.
85. Gasparini L, Xu H: Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends in Neurosciences 2003, 28:404-406.
86. Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I: Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neuroscience Letters 2001, 316:129-132.
87. Schulze PC, Gielen S, Schuler G, Hambrecht R: Chronic heart failure and skeletal muscle catabolism: effects of exercise training. International Journal of Cardiology 2002, 85:141-149.